Bath & Body Works (NYSE:BBWI - Get Free Report) had its price objective decreased by stock analysts at Barclays from $35.00 to $30.00 in a report issued on Friday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Barclays's price target indicates a potential upside of 6.53% from the stock's current price.
Several other research analysts also recently commented on the company. Wells Fargo & Company raised their price objective on Bath & Body Works from $40.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Raymond James reduced their price objective on Bath & Body Works from $46.00 to $37.00 and set an "outperform" rating on the stock in a report on Thursday, April 17th. UBS Group raised their price objective on Bath & Body Works from $32.00 to $36.00 and gave the stock a "neutral" rating in a report on Tuesday, May 20th. Citigroup raised their price objective on Bath & Body Works from $36.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, May 20th. Finally, Telsey Advisory Group restated an "outperform" rating and set a $38.00 price objective (down from $43.00) on shares of Bath & Body Works in a report on Thursday. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Bath & Body Works currently has a consensus rating of "Moderate Buy" and a consensus price target of $42.00.
Read Our Latest Research Report on Bath & Body Works
Bath & Body Works Price Performance
Shares of NYSE:BBWI traded down $0.42 during trading on Friday, hitting $28.16. The company had a trading volume of 6,154,657 shares, compared to its average volume of 5,000,590. The stock has a market cap of $6.00 billion, a price-to-earnings ratio of 6.87, a price-to-earnings-growth ratio of 0.92 and a beta of 1.87. Bath & Body Works has a one year low of $24.96 and a one year high of $52.99. The company has a fifty day simple moving average of $30.07 and a two-hundred day simple moving average of $33.97.
Bath & Body Works (NYSE:BBWI - Get Free Report) last issued its quarterly earnings results on Thursday, May 29th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.02. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.42 billion. During the same period in the prior year, the business posted $0.38 earnings per share. The company's revenue for the quarter was up 2.9% on a year-over-year basis. On average, equities research analysts anticipate that Bath & Body Works will post 3.3 earnings per share for the current year.
Bath & Body Works announced that its board has authorized a share buyback program on Thursday, February 27th that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.
Institutional Trading of Bath & Body Works
A number of institutional investors have recently made changes to their positions in BBWI. Golden State Wealth Management LLC acquired a new stake in Bath & Body Works during the 4th quarter worth about $26,000. SRS Capital Advisors Inc. lifted its position in Bath & Body Works by 99.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 659 shares of the company's stock worth $26,000 after acquiring an additional 329 shares during the period. SVB Wealth LLC acquired a new stake in Bath & Body Works during the 1st quarter worth about $35,000. Geneos Wealth Management Inc. lifted its position in Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock worth $35,000 after acquiring an additional 801 shares during the period. Finally, Lindbrook Capital LLC lifted its position in Bath & Body Works by 81.9% during the 4th quarter. Lindbrook Capital LLC now owns 957 shares of the company's stock worth $37,000 after acquiring an additional 431 shares during the period. Institutional investors and hedge funds own 95.14% of the company's stock.
About Bath & Body Works
(
Get Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Featured Articles
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
